{
    "clinical_study": {
        "@rank": "4928", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Other", 
                "description": "1 MAP cycle (incl. 2 HDMTX Courses using SOC rescue 15mg/m2)\n1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Other", 
                "description": "1 MAP cycle (incl. 2 HDMTX Courses using SOC rescue 15mg/m2)\n1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5 or 30mg/m2*\n*Dose will depend on outcome from Cohort 1"
            }
        ], 
        "brief_summary": {
            "textblock": "An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the [6R]\n      5,10-methylenetetrahydrofolate Dose with Most Favorable Safety Prospect and Confirmed\n      Ability to Mitigate High-Dose Methotrexate Induced Toxicity during Treatment of Osteosarcoma\n      Patients"
        }, 
        "brief_title": "Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.", 
        "condition": "Osteosarcoma", 
        "condition_browse": {
            "mesh_term": "Osteosarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects meeting all of the following criteria may be eligible for the study:\n\n          1. Patients must have histological evidence of osteosarcoma including metastatic\n             osteosarcoma.\n\n          2. Patients must be eligible for high-dose methotrexate treatment (HDMTX) according to\n             the MAP treatment schedule described in the study protocol (see Appendix 1) and\n             fulfill all of the criteria below prior to first course of HDMTX in the study.\n\n               1. Serum MTX: \u2264 0.1\u00b5mol/L\n\n               2. Neutrophils: \u2265 0.25 x 109/L\n\n               3. Platelets: \u2265 50 x 109/L\n\n               4. Serum bilirubin: \u2264 1.25 x ULN\n\n               5. GFR \u2265 70 mL/min/1.73 m2\n\n               6. No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential\n                  HDMTX administration, at the discretion of the investigator.\n\n          3. Patients must be enrolled in HDMTX course 1, 3 or 5 of the MAP treatment schedule(see\n             Appendix 1).\n\n          4. Patients enrolled in HDMTX course 3 or 5 must have a history of successful\n             advancement from first to second HDMTX course within the same MAP cycle in all prior\n             MAP cycles, i.e. fulfilling all of the following criteria 8 days after start of first\n\n             HDMTX course within the same MAP cycle:\n\n               1. Serum MTX: \u2264 0.1\u00b5mol/L\n\n               2. Neutrophils: \u2265 0.25 x 109/L\n\n               3. Platelets: \u2265 50 x 109/L\n\n               4. Serum bilirubin: \u2264 1.25 x ULN\n\n               5. GFR \u2265 70 mL/min/1.73 m2\n\n               6. No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential\n                  HDMTX administration, at the discretion of the investigator.\n\n          5. Patients enrolled in HDMTX course 3 or 5 must have a history of successful\n             advancement to next MAP cycle after all prior MAP cycles, i.e. fulfilling all of the\n             following criteria 8 days after start of the second HDMTX course in previous MAP\n             cycle:\n\n               1. Serum MTX: \u2264 0.1\u00b5mol/L\n\n               2. Neutrophils: \u2265 0.75 x 109/L\n\n               3. Platelets: \u2265 75 x 109/L\n\n               4. Serum bilirubin: \u2264 1.25 x ULN\n\n               5. GFR \u2265 70 mL/min/1.73 m2\n\n               6. No AE Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential\n                  HDMTX administration, at the discretion of the investigator.\n\n          6. Patients must be 12-40 years of age.\n\n          7. Sexually active females of childbearing potential: Must be surgically sterile, or\n             compliant with a contraceptive regimen during and for six (6) months after last MTX\n             dose in MAP regimen; must have a negative serum or urine pregnancy test (within seven\n             (7) days before study enrolment) and must not be lactating.\n\n          8. Sexually active males: Must be surgically sterile or compliant with a contraceptive\n             regimen during and for six (6) months after last MTX dose in MAP regimen.\n\n          9. Patient, parent(s), or guardian(s), as appropriate, is/are willing and able to\n             provide signed informed consent.\n\n         10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory\n             tests, and other study procedures specified in the protocol.\n\n         11. Patients who have undergone surgical resection of their tumor must have recovered\n             from their surgery and be eligible to continue on the MAP regimen; any post-operative\n             complications should be resolved to NCI CTCAE v4.0 Grade 1 or better.\n\n        Exclusion Criteria:\n\n        Subjects meeting any of the following criteria are not eligible for participation:\n\n          1. Involvement in another clinical trial within 30 days before enrolment in the study.\n\n          2. Hypersensitivity to Calcium Folinate.\n\n          3. Previous treatment with glucarpidase.\n\n          4. Known serious concomitant systemic disorders (e.g., active infection including HIV,\n             liver dysfunction, cardiac disease) that, in the opinion of the investigator, would\n             compromise the patient's ability to complete the study"
            }, 
            "gender": "Both", 
            "maximum_age": "40 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987102", 
            "org_study_id": "ISO-MTX-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are \u2264 0.1 \u00b5mol/L, in accordance with COG management recommendations.\nAll patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.", 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug", 
                "other_name": "Calcium Folinate"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "The enrolled patients will be treated according to the MAP schedule and will receive the study drug [6R] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are \u2264 0.1 \u00b5mol/L, in accordance with COG management recommendations.\nAll patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate\u00ae dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.", 
                "intervention_name": "[6R] 5,10-methylenetetrahydrofolate", 
                "intervention_type": "Drug", 
                "other_name": "Modufolin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Tetrahydrofolates", 
                "Levoleucovorin"
            ]
        }, 
        "keyword": [
            "Methotrexate", 
            "rescue treatment"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "contact": {
                "email": "mikael.eriksson@med.lu.se", 
                "last_name": "Mikael Eriksson, MD, PhD", 
                "phone": "+46(0)46177507"
            }, 
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden", 
                    "zip": "22185"
                }, 
                "name": "Department of Oncology, Sk\u00e5ne University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "eva.rongard@isofolmedical.com", 
            "last_name": "Eva Rong\u00e5rd", 
            "phone": "+46(0)709249425"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Poland: Ministry of Health and Social Welfare", 
                "Hungary: National Institute of Pharmacy"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Characterization (frequency and severity grade) of toxicity reported for each course of HDMTX treatment with folate rescue therapy and continuing until eight (8) days after start of HDMTX administration, per NCI CTCAE v4.0", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of administered HDMTX courses with [6R] 5,10-methylenetetrahydrofolate rescue classified as having met the criteria for successful advancement.", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected 8 weeks"
        }, 
        "source": "Isofol Medical AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isofol Medical AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}